N/A
N=190
Delivery of Pharmacogenetic Testing in a Community Pharmacy Setting
Pharmacogenetics
Bottom Line
View on ClinicalTrials.gov: NCT02937545 ↗Enrolled (actual)
190
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcome: Primary: Number of Patient Participants' Acceptance of PGx Services Offered in Community Pharmacy Setting — 14; 13 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Medication Therapy Management (Other); Pharmacogenetic testing (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Duke University
- Primary completion
- Sep 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patient Participants' Acceptance of PGx Services Offered in Community Pharmacy Setting |
14; 13 | — |
| PRIMARY Number of Patient Participants Who Recalled All Test Results |
13; 15 | — |
| PRIMARY Number of Patient Participants Who Considered Time With Pharmacist to be Worthwhile |
16; 16 | — |
| PRIMARY Number of Patient Participants' With High Medication Adherence |
15; 12 | — |
| PRIMARY Number of Patient Participants With High Medication Adherence (Post-study) |
11; 9 | — |
| PRIMARY Number of Patient Participants Who Reported Understanding of Implications of Test Results |
11; 16 | — |
| SECONDARY Number of Pharmacist Participants Who Reported Strong Likelihood to Continue to Deliver PGx Testing |
0; 2 | — |
| SECONDARY Average Score of PGx Knowledge Assessment by Pharmacist Participants |
5.4; 5.3 | — |
| SECONDARY Number of Pharmacist Participants Who Reported 'Reimbursement' as Most Common Barrier to Delivery of PGx Testing |
5; 3 | — |
| SECONDARY Number of Participating Pharmacists Who Feel Qualified to Deliver PGx Testing |
7; 7 | — |
Summary
This study aims to compare patient use of and satisfaction with community pharmacist-delivered pharmacogenetic (PGx) testing delivered along or as part of a medication therapy management (MTM) service. Pharmacist and patient outcome measures will be collected by surveys, interviews, and review of pharmacy records.
Eligibility Criteria
Inclusion Criteria
- Pharmacist participants must be community pharmacists licensed and practicing in North Carolina
- Patient participants must be prescribed one of the 10 eligible medications (aripiprazole, carisoprodol, celecoxib, citalopram, clopidogrel, metoprolol, nortriptyline, paroxetine, simvastatin, warfarin)
- Patient participants must be able to consent to participating and testing on their own, and be able to read English
Exclusion Criteria
- Patients who have previously undergone pharmacogenetic testing will not be eligible.
Data sourced from ClinicalTrials.gov (NCT02937545). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.